22:58 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Basal cell carcinoma (BCC) Mouse studies suggest combining LGR5, LRP6 or PORCN inhibitors with Erivedge vismodegib could help treat BCC. In two mouse models of BCC, diphtheria toxin-mediated depletion of LGR5 decreased tumor burden compared...
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
20:04 , Aug 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Alt-neoantigens

Neoantigens derived from alternative splicing could broaden the target space for cancer vaccines and T cell therapies, according to two studies published this month. While questions remain about whether they are sufficiently immunogenic to create...
18:31 , Aug 17, 2018 |  BC Week In Review  |  Financial News

RegenxBio raises $201.8M follow-on

RegenxBio Inc. (NASDAQ:RGNX) raised $201.8 million through the sale of 3.1 million shares at $65 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, Barclays and Raymond James. The number includes a 405,000 share...
20:46 , Aug 13, 2018 |  BC Extra  |  Preclinical News

Polygenic scores increase disease risk prediction

Two studies in Nature Genetics suggest that aggregating SNPs, instead of assessing single SNPs, to generate risk scores from genome-wide association studies (GWAS) could improve predictions for disease risk. The use of individual gene variants identified...
18:37 , Aug 10, 2018 |  BC Extra  |  Financial News

RegenxBio raises $175.5M follow-on

RegenxBio Inc. (NASDAQ:RGNX) raised $175.5 million through the sale of 2.7 million shares at $65 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, Barclays and Raymond James. On Wednesday, the company disclosed a treatment-related...
00:21 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

RegenxBio discloses second serious AE for hypercholesterolemia gene therapy

RegenxBio Inc. (NASDAQ:RGNX) said RGX-501 led to a second treatment-related serious adverse event in a Phase I/II trial to treat homozygous familial hypercholesterolemia (HoFH). The open-label, international trial has enrolled six patients to receive a single...
00:01 , Aug 3, 2018 |  BC Innovations  |  Targets & Mechanisms

Oxitope’s oxidation play

A trio of papers from a UCSD group has found a connection between oxidized lipids and inflammation in atherosclerosis, osteoporosis and ischemia injury, breathing new life into the once popular “oxidation hypothesis” of atherosclerosis. The authors...
20:26 , Jul 20, 2018 |  BioCentury  |  Emerging Company Profile

Selective Regeneration

Surrozen Inc. is making tunable bispecific antibodies molecules it believes can overcome a major hurdle that has prevented other companies from tapping the Wnt pathway for regenerative medicine: namely, the inability to drug specific members...
23:29 , Apr 13, 2018 |  BioCentury  |  Tools & Techniques

Personalizing prevention

PlaqueTec Ltd. is working to bring personalized medicine to the cardiovascular space with a device that samples local concentrations of molecules near atherosclerotic plaques. By using these samples to identify prognostic and predictive biomarkers, the...